65 related articles for article (PubMed ID: 11583287)
1. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients.
Novotný J; Petruzelka L; Vedralová J; Kleibl Z; Matous B; Juda L
Neoplasma; 2001; 48(3):188-91. PubMed ID: 11583287
[TBL] [Abstract][Full Text] [Related]
2. HER-family gene amplification and expression in resected pancreatic cancer.
te Velde EA; Franke AC; van Hillegersberg R; Elshof SM; de Weger RW; Borel Rinkes IH; van Diest PJ
Eur J Surg Oncol; 2009 Oct; 35(10):1098-104. PubMed ID: 19304440
[TBL] [Abstract][Full Text] [Related]
3. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
4. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
5. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
Stoecklein NH; Luebke AM; Erbersdobler A; Knoefel WT; Schraut W; Verde PE; Stern F; Scheunemann P; Peiper M; Eisenberger CF; Izbicki JR; Klein CA; Hosch SB
J Clin Oncol; 2004 Dec; 22(23):4737-45. PubMed ID: 15570074
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
7. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
8. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma.
Huang C; Huang R; Chang W; Jiang T; Huang K; Cao J; Sun X; Qiu Z
Neoplasma; 2012; 59(1):52-61. PubMed ID: 22082308
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
10. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
Casneuf VF; Fonteyne P; Van Damme N; Demetter P; Pauwels P; de Hemptinne B; De Vos M; Van de Wiele C; Peeters M
Cancer Invest; 2008 Oct; 26(8):852-9. PubMed ID: 18853313
[TBL] [Abstract][Full Text] [Related]
11. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma.
Xia W; Lau YK; Zhang HZ; Liu AR; Li L; Kiyokawa N; Clayman GL; Katz RL; Hung MC
Clin Cancer Res; 1997 Jan; 3(1):3-9. PubMed ID: 9815530
[TBL] [Abstract][Full Text] [Related]
12. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage.
Thybusch-Bernhardt A; Beckmann S; Juhl H
Int J Surg Investig; 2001; 2(5):393-400. PubMed ID: 12678544
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer.
Lundin J; Nordling S; von Boguslawsky K; Roberts PJ; Haglund C
Anticancer Res; 1995; 15(6B):2659-68. PubMed ID: 8669843
[TBL] [Abstract][Full Text] [Related]
15. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases.
Chen J; Li Q; Wang C; Wu J; Zhao G
Ann Surg Oncol; 2010 Jun; 17(6):1555-63. PubMed ID: 20069460
[TBL] [Abstract][Full Text] [Related]
17. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
[TBL] [Abstract][Full Text] [Related]
20. [Overexpression of c-erbB-2 oncogene in primary ovarian cancers: incidence and prognostic significance in 243 patients].
Meden H; Marx D; Rath W; Kuhn W; Hinney B; Schauer A
Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):667-73. PubMed ID: 1360438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
